Suppr超能文献

靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主要蛋白酶(M)的抑制剂的研究进展

Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M).

作者信息

Yang Yue, Luo Yi-Dan, Zhang Chen-Bo, Xiang Yang, Bai Xin-Yue, Zhang Die, Fu Zhao-Ying, Hao Ruo-Bing, Liu Xiao-Long

机构信息

School of Medicine, Yan'an University, Yan'an 716000, China.

College of Physical Education, Yan'an University, Yan'an 716000, China.

出版信息

ACS Omega. 2024 Aug 2;9(32):34196-34219. doi: 10.1021/acsomega.4c03023. eCollection 2024 Aug 13.

Abstract

Since 2019, the novel coronavirus (SARS-CoV-2) has caused significant morbidity and millions of deaths worldwide. The Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2 and its variants, has further highlighted the urgent need for the development of effective therapeutic agents. Currently, the highly conserved and broad-spectrum nature of main proteases (M) renders them of great importance in the field of inhibitor study. In this study, we categorize inhibitors targeting M into three major groups: mimetic, nonmimetic, and natural inhibitors. We then present the research progress of these inhibitors in detail, including their mechanism of action, antiviral activity, pharmacokinetic properties, animal experiments, and clinical studies. This review aims to provide valuable insights and potential avenues for the development of more effective antiviral drugs against SARS-CoV-2.

摘要

自2019年以来,新型冠状病毒(SARS-CoV-2)已在全球范围内导致大量发病和数百万人死亡。由SARS-CoV-2及其变体引起的2019冠状病毒病(COVID-19)进一步凸显了开发有效治疗药物的迫切需求。目前,主要蛋白酶(M)的高度保守性和广谱性使其在抑制剂研究领域具有重要意义。在本研究中,我们将针对M的抑制剂分为三大类:模拟物、非模拟物和天然抑制剂。然后,我们详细介绍了这些抑制剂的研究进展,包括它们的作用机制、抗病毒活性、药代动力学特性、动物实验和临床研究。本综述旨在为开发更有效的抗SARS-CoV-2抗病毒药物提供有价值的见解和潜在途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4be/11325518/05c6aec445ca/ao4c03023_0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验